New Option for AL Amyloidosis: Daratumumab Added to CyBorD New Option for AL Amyloidosis: Daratumumab Added to CyBorD

The addition of daratumumab to the standard CyBorD regimen produced ' substantial ' increases in hematologic response rates and delayed the time to organ failure.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news